London Co. of Virginia Cuts Holdings in Bruker Corporation $BRKR

London Co. of Virginia trimmed its position in Bruker Corporation (NASDAQ:BRKR) by 25.2% in the third quarter, HoldingsChannel reports. The firm owned 3,008,493 shares of the medical research company’s stock after selling 1,015,320 shares during the quarter. London Co. of Virginia’s holdings in Bruker were worth $97,746,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Orbis Allan Gray Ltd bought a new position in shares of Bruker in the second quarter valued at approximately $192,735,000. AQR Capital Management LLC lifted its holdings in Bruker by 125.3% during the second quarter. AQR Capital Management LLC now owns 3,326,820 shares of the medical research company’s stock worth $137,065,000 after acquiring an additional 1,850,215 shares during the period. Sculptor Capital LP boosted its position in Bruker by 18.3% in the second quarter. Sculptor Capital LP now owns 3,074,801 shares of the medical research company’s stock worth $126,682,000 after purchasing an additional 476,363 shares during the last quarter. Brown Advisory Inc. boosted its position in Bruker by 13.9% in the second quarter. Brown Advisory Inc. now owns 2,746,163 shares of the medical research company’s stock worth $113,142,000 after purchasing an additional 336,026 shares during the last quarter. Finally, Vaughan Nelson Investment Management L.P. grew its stake in Bruker by 61.6% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 2,090,155 shares of the medical research company’s stock valued at $67,909,000 after purchasing an additional 796,510 shares during the period. Institutional investors own 79.52% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. UBS Group reiterated a “neutral” rating and set a $49.00 target price on shares of Bruker in a research note on Friday, February 13th. Bank of America increased their price target on shares of Bruker from $43.00 to $60.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Barclays decreased their price objective on shares of Bruker from $55.00 to $50.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research report on Monday, December 29th. Finally, TD Cowen dropped their target price on shares of Bruker from $53.00 to $43.00 and set a “hold” rating on the stock in a research note on Friday, February 13th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, five have given a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $50.38.

Bruker Stock Performance

Shares of BRKR opened at $32.76 on Tuesday. Bruker Corporation has a 52-week low of $28.53 and a 52-week high of $56.22. The stock’s 50-day simple moving average is $43.13 and its 200 day simple moving average is $41.11. The company has a debt-to-equity ratio of 0.75, a quick ratio of 0.87 and a current ratio of 1.73. The stock has a market capitalization of $4.99 billion, a price-to-earnings ratio of -218.40, a price-to-earnings-growth ratio of 2.02 and a beta of 1.19.

Bruker (NASDAQ:BRKR) last posted its earnings results on Thursday, February 12th. The medical research company reported $0.59 earnings per share for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.06). Bruker had a negative net margin of 0.25% and a positive return on equity of 13.56%. The company had revenue of $977.20 million for the quarter, compared to analysts’ expectations of $964.61 million. During the same period in the previous year, the firm earned $0.76 EPS. The firm’s quarterly revenue was down .2% compared to the same quarter last year. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. Research analysts forecast that Bruker Corporation will post 2.69 EPS for the current fiscal year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 7th. Investors of record on Monday, March 23rd will be paid a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 23rd. This represents a $0.20 annualized dividend and a yield of 0.6%. Bruker’s payout ratio is currently -133.33%.

Insider Buying and Selling

In related news, VP Mark Munch sold 7,000 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $55.00, for a total transaction of $385,000.00. Following the sale, the vice president owned 128,443 shares of the company’s stock, valued at approximately $7,064,365. This represents a 5.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders have sold a total of 11,000 shares of company stock worth $554,280 over the last three months. 27.30% of the stock is currently owned by insiders.

Bruker Company Profile

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.